The paradox of immunosuppressants and COVID-19

Guang-Shing Cheng; Scott E Evans

doi:10.1183/13993003.02828-2021

The paradox of immunosuppressants and COVID-19

Eur Respir J. 2022 Apr 7;59(4):2102828. doi: 10.1183/13993003.02828-2021. Print 2022 Apr.

Authors

Guang-Shing Cheng¹, Scott E Evans²

Affiliations

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center and Division of Pulmonary Critical Care and Sleep Medicine, University of Washington School of Medicine, Seattle, WA, USA gcheng2@fredhutch.org.
² Dept of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Lessons learned from a large registry analysis show worse COVID-19 outcomes for patients previously exposed to glucocorticoids https://bit.ly/306rNrk

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

COVID-19*
Humans
Immunosuppressive Agents / therapeutic use
Prognosis
SARS-CoV-2

Substances

Immunosuppressive Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding